Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

ABSTRACT: RATIONALE: Surgery may remove residual disease in patients with gastrointestinal stromal tumor that is responding to imatinib mesylate. It is not yet known whether surgery is more effective than continued imatinib mesylate in treating patients with metastatic gastrointestinal stromal tumor. PURPOSE: This randomized phase III trial is studying giving imatinib mesylate therapy together with surgery to see how well it works compared with imatinib mesylate alone in treating patients with metastatic gastrointestinal stromal tumor that is responding to imatinib mesylate.

DISEASE(S): Metastatic Gastro-intestinal Stromal Tumor,Sarcoma,Gastrointestinal Stromal Tumor,Soft Tissue,Gastrointestinal Stromal Tumors

PROVIDER: 2076430 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of human gastrointestinal stromal tumour is predictive of rapid response to imatinib mesylate

Project description:Gene expression profiling using oligonucleotide microarrays performed on tumor samples obtained before and after imatinib mesylate (IM) therapy. Rapid responding (to IM) samples were compared to non-responding/stable disease samples as measured by CT scan measurements to identify a gene signature that can predict rapid response to IM. Experiment Overall Design: 54 samples, 29 pre-treatment biopsy samples, 25 post-treatment/post-surgery tumor samples from Gastrointestinal Stromal Tumors

2009-12-02 | E-GEOD-15966 | biostudies-arrayexpress

Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST)

2009-11-24 | GSE15966 | GEO

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor

Project description:siRNA knock-down of ZNF genes determined to impact gastrointestinal stromal tumor response to imatinib were used to determine functional significance of ZNFs and identify key targets related to imatinib resistance.

2013-08-01 | GSE40080 | GEO

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor

2013-08-01 | E-GEOD-40080 | biostudies-arrayexpress

Gene expression analysis of imatinib-resistant GIST

Project description:To reveal mechanisms for acquired imatinib resistance in gastrointestinal stromal tumor (GIST), we have analyzed several cell lines with resistance to imatinib.

2016-12-27 | GSE69465 | GEO

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Project description:Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage IV colorectal cancer. Imatinib mesylate may interfere with the growth of tumor cells by blocking certain enzymes necessary for cancer cell growth

| 2007915 | ecrin-mdr-crc

Imatinib Treatment of GIST882

Project description:Gastrointestinal Stromal Tumor frequently harbor mutations in the KIT receptor tyrosine kinase and depend on its activity for growth. This underlies the efficacy of imatinib, a inhibitor of KIT activity, in GIST management. GIST882 is a patient derived GIST cell line that harbor a K640E exon 13 KIT mutation and is sensitive to imatinib treatment. To analyze the downstream effect of KIT inhibition, GIST882 cells were treated for 8 hours with 1μM Imatinib.

2010-10-13 | GSE22433 | GEO

Homo sapiens

Project description:ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor

| PRJNA172857 | ENA

Imatinib Mesylate Oral Solution 400mg/5ml with GleevecÂ (Imatinib mesylate) Tablets 400mg in adult human subjects with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.

Project description:Intervention1: Imatinib Mesylate Oral Solution 400mg/5ml: Dose: 5 ml(400mg), Frequency: once Daily, Route of Administration: Oral, Duration: 16 Days Control Intervention1: GleevecÂ (Imatinib mesylate) Tablets 400mg: Dose: Single Dose(1 tablet x 400 mg), Frequency: once Daily, Route of Administration: Oral, Duration: 16 Days Primary outcome(s): To compare and evaluate the multiple dose oral bioavailability of Imatinib Mesylate Oral Solution 400mg/5ml of Shilpa Medicare Limited with GleevecÂ (Imatinib mesylate) Tablets 400mg of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, in adult human patients with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.Timepoint: Day:1-Pre-dose blood sample within 1.00 hour prior to dosing, Day:6 and 14- Pre-dose blood sample (-48.0) and Day:7 and 15- Pre-dose blood sample (-24.0) within 1.00 hour prior to dosing, Day:8and16- Pre-dose blood sample (0.0) within 1 hour prior to dosing for 0.5 hours, 1.0 hrs., 1.5 hrs., 2.0 hrs., 2.5 hrs., 3.0 hrs., 3.5 hrs., 4.0 hrs., 5.0 hrs., 6.0 hrs., 8.0 hrs., 10.0 hrs., 12.0 hrs., 16.0 hrs. within Â± 02 minutes, Day:09and17 24 hrs. within Â± 02 minutes Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Pre-numbered or coded identical Containers Blinding and masking:Open Label

| 2594937 | ecrin-mdr-crc

Imatinib Treatment of GIST882

2010-10-13 | E-GEOD-22433 | biostudies-arrayexpress